- ►diabetesjournals.org PA Hollander, P Levy, MS Fineman, DG Maggs … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Treatment with pramlintide 120 μg BID led to a sustained reduction
from baseline in HbA 1c (−0.68 and −0.62% at weeks 26 and 52, respectively),
which was significantly greater than that seen with placebo (P < 0.05). The ... Cited by 167 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org C Levetan, LL Want, C Weyer, SA Strobel, J … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In this study, 18 patients (16 of whom could be
evaluated) with type 1 diabetes (age 44 ± 11 years, HbA 1c 8.2 ± 1.3% [mean ±
SD]) were given mealtime injections of 30 μg pramlintide tid for 4 weeks ... Cited by 68 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org C Weyer, A Gottlieb, DD Kim, K Lutz, S … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In this randomized, single-blind,
placebo-controlled, five-way crossover study, 19 subjects with type 1 diabetes
using regular insulin and 21 subjects with type 1 diabetes using insulin ... Cited by 58 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org A Ceriello, L Piconi, L Quagliaro, Y Wang, … - Diabetes Care, 2005 - Am Diabetes Assoc OBJECTIVE—Oxidative stress has been shown to be increased in the postprandial
period in patients with diabetes and has been implicated in the pathogenesis of
micro- and macrovascular complications. The aim of this post hoc analysis ... Cited by 54 - Related articles - All 6 versions
DG Maggs, M Fineman, J Kornstein, T Burrell … - Diabetes/Metabolism Reviews - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 48 - Related articles - BL Direct - All 3 versions
P Hollander, R Ratner, M Fineman, S Strobel … - Diabetes Obesity and Metabolism, 2003 - interscience.wiley.com Methods: To assess whether this profile of pramlintide is observed in patients
approaching, but not yet reaching, glycaemic targets, we conducted a pooled post
hoc analysis of the two trials, including all patients with an entry HbA 1c ... Cited by 41 - Related articles - BL Direct - All 3 versions
SL Aronoff, K Berkowitz, B Shreiner, L Want - Diabetes Spectrum, 2004 - Am Diabetes Assoc Insulin and glucagon are potent regulators of glucose metabolism. For decades,
we have viewed diabetes from a bi-hormonal perspective of glucose regulation.
This perspective is incomplete and inadequate in explaining some of the ... Cited by 35 - Related articles - BL Direct - All 2 versions
D Maggs, L Shen, S Strobel, D Brown, O … - Metabolism, 2003 - Elsevier An unresolved problem in the management of type 2 diabetes is that improvement
of glycemic control with insulin, insulin secretagogues, and insulin sensitizers
is often accompanied by undesired weight gain. This problem is of ... Cited by 30 - Related articles - All 13 versions
- ►hospitalprivadosa.com.ar [PDF] T Davis, SV Edelman - Medical Clinics of North America, 2004 - Elsevier Type 2 diabetes leads to a tremendous amount of death and disability and uses a
large portion of the health care dollar [4]. Although diabetes is associated
with multiple disorders with distinct pathologic mechanisms, insulin ... Cited by 25 - Related articles - BL Direct - All 4 versions
EL Kleppinger, EM Vivian - The Annals of pharmacotherapy, 2003 - Harvey Whitney Books DATA SYNTHESIS: Clinical trials have demonstrated that amylin in combination
with insulin controls postprandial glucose levels by decreasing food intake,
slowing gastric emptying, and suppressing glucagon secretion. Clinical ... Cited by 20 - Related articles - BL Direct - All 4 versions
